Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Taiji Group's Board of Directors has approved several annual resolutions, proposing not to distribute profits and to reappoint the auditing firm.
Zhongfang Network Data: Chongqing Taiji Industrial (Group) Co., Ltd. held the 37th meeting of the 10th Board of Directors on March 25, 2026, reviewing and approving several important annual proposals. The core decision includes: the company plans not to distribute profits for the fiscal year 2025, meaning no cash dividends, no stock bonuses, and no capitalization of capital reserves into share capital, mainly to ensure funding needs for production operations and capacity construction in 2026. Financial data shows that the net profit attributable to shareholders of the listed company for the fiscal year 2025 is 121 million yuan, and the profit available for distribution to investors at the end of the year is 824 million yuan.
The meeting also approved the “2025 Annual Report and Summary,” and reviewed matters such as the provision for asset impairment and the financial budget for 2026. To meet operational needs, the Board of Directors agreed to apply for a comprehensive credit limit for 2026, which still needs to be submitted to the shareholders’ meeting for approval. In terms of related transactions, the Board approved the proposal to re-sign the “Financial Service Agreement” with China National Pharmaceutical Group Finance Co., Ltd., with related directors abstaining from voting.
In addition, the Board resolved to reappoint Lixin Certified Public Accountants as the auditing agency for the company’s 2026 financial report and internal control audit. The meeting also approved the technical transformation project for the pre-treatment workshop of the fully-owned subsidiary, Taiji Group Chongqing Traditional Chinese Medicine No. 2 Factory, located in Dongzikou, as well as the external donation budget totaling 2.26 million yuan for 2026. To optimize the asset structure, the company plans to publicly transfer its equity in Chongqing Jinke Commercial Factoring Co., Ltd. and Chongqing Jinke Financial Factoring Co., Ltd.
The above-mentioned proposals concerning profit distribution, comprehensive credit, related transactions, and the reappointment of the auditing agency will be submitted to the company’s 2025 annual shareholders’ meeting for review.
A wealth of information and precise interpretations can be found in the Sina Finance APP.